Trusted Resources: Education
Scientific literature and patient education texts
Maroteaux Lamy Syndrome
source: National Organization for Rare Disorders, Inc.
year: N/A
summary/abstract:Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI; MPS VI) is a rare genetic disorder characterized by complete or partial lack of activity of the enzyme arylsulfatase B (also called N-acetylgalactosamine-4-sulfatase), encoded by the ARSB gene. Deficiency or absence of this enzyme activity leads to the accumulation of complex carbohydrates called glycosaminoglycans (previously known as mucopolysaccharides) in the body. Abnormal accumulation of mucopolysaccharides leads to progressive involvement of multiple organ systems. The symptoms and severity of Maroteaux-Lamy syndrome can vary dramatically from one person to another; some individuals only develop mild symptoms, while others develop severe, even life-threatening complications.
Common symptoms can include coarse facial features, corneal clouding, joint abnormalities, various skeletal malformations, an abnormally enlarged liver and/or spleen (hepatosplenomegaly), and hearing loss. Cardiac disease and restrictive pulmonary disease can also occur. Intelligence is usually not affected. In 2005, the Food and Drug Administration (FDA) approved the enzyme replacement therapy known as Naglazyme® for the treatment of Maroteaux-Lamy syndrome. Maroteaux-Lamy syndrome occurs due to mutations in the ARSB gene and is inherited as an autosomal recessive disorder.
read more
Related Content
-
Mucopolysaccharidosis Type I Disease Prevalence Among Patients With Idiopathic Short Stature in Saudi Arabia: Protoc...Since the underlying cause of idiopathic...
-
Disease Burden, Management Patterns and Multidisciplinary Clinical Approaches for Patients With MPS IVA and VI in Se...There is a paucity of real-world epidemi...
-
Mass General – Lysosomal Storage Disorders ProgramThe Lysosomal Storage Disorders Program ...
-
Mucopolysaccharidosis Type III – Sanfilippo SyndromeMucopolysaccharidosis type III (MPS III)...
-
Clinical Outcomes of Laminoplasty for Patients With Lysosomal Storage Disease Including Mucopolysaccharidosis and Mu...Although the clinical efficacy of lamino...
-
MPS and ML Overview: 2021 Insights and Overviewhttps://www.youtube.com/watch?v=e2tOMBvY...
-
Damage of the Cardiovascular System in Lysosomal Storage Disease – MucopolysaccharidosisThe analysis of literature data reflecti...